biotech

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.
Theranos, once a Silicon Valley unicorn promising investors and partners like Walgreens a simple blood-testing solution, is a cautionary tale for biotech investors.
It may be tempting to try, but fading strong Monday's hasn't been a good strategy lately.
With the resurgent market, traders are moving back into the big tech names such as Apple and Facebook.
These names are moving up or down in a big way ahead of releasing drug-trial results.
Bonds and the dollar constrain big-market moves.
This underperformance is being caused by pockets of weakness in bigger-cap names.
As interest rate fears ease slightly, indexes rebound.
Worries about interest rates are unlikely to go away easily.
The key for the overall market now is that it hold above today's early lows.

Columnist Conversations

join me for a free webinar after the close today as we discuss some of those calendar rituals, like 'sell in m...
AAII Bulls ticked up this week to 38.6% which is the highest they have been since February, although only marg...
I am on the ground in San Fran. to cover PayPal's (PYPL) big investor day today. Had a chance to talk with so...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.